Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal antihistamine versus corticosteroid versus combination therapy for allergic rhinitis gene expression
ACTRN12616001439437Phase 4Completed
- Sponsor
- Griffith University
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of azelastine and fluticasone propionate in allergic rhinitis (AR) (3 arms), sponsored by Griffith University. Primary endpoint: Gene expression profiles in nasal mucosal cells. Started Nov 2016; status: completed.
02
Drugs
azelastinefluticasone propionate
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ACTRN12616001439437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001439437.